Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial

C. Davis, John; van der Heijde, Désirée; Braun, Jürgen; Dougados, Maxime; J. Cush, John; O. Clegg, Daniel; Kivitz, Alan; Fleischmann, Roy; D. Inman, Robert; Tsuji, Wayne; the Enbrel Ankylosing Spondylitis Study Group, for

doi:10.1002/art.11325

Public

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial

Published in Arthritis & Rheumatism • Nov 1, 2003

Authors:

John C. Davis

Désirée van der Heijde

Jürgen Braun

Abstract

OBJECTIVE: To determine the safety and efficacy of etanercept in a multicenter, randomized, placebo-controlled, double-blind trial of adults with moderate to severe active ankylosing spondylitis (AS). METHODS: Patients (n = 277) were treated with either etanercept 25 mg (n = 138) or placebo (n = 139...

Subject

Etanercept

Medicine

Ankylosing spondylitis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!